|
New Leaf Venture Partners Appoints Dr.
Srinivas Akkaraju as Managing Director and Lead of the Firm’s
West Coast Biopharmaceuticals Practice
NEW YORK--(BUSINESS WIRE)-- New Leaf Venture Partners (NLV
Partners) announced today the appointment of Srinivas Akkaraju,
M.D., Ph.D., as Managing Director and lead of NLV Partners’ West
Coast biopharmaceuticals practice. Dr. Akkaraju’s appointment is
effective immediately.
“Dr. Akkaraju will be a tremendous addition to NLV Partners, and
we are delighted to welcome him to the team,” stated Philippe
Chambon, M.D., Ph.D., Managing Director of NLV Partners. “We
expect his broad network of contacts and extensive experience in
the biopharma industry will prove invaluable for the firm and to
our portfolio companies, particularly on the West Coast.”
Dr. Akkaraju commented, "I am excited to join NLV Partners. The
depth, quality and cohesiveness of NLV Partners attracted me to
the firm, and I look forward to the opportunity to continue
developing as an investor in a dynamic and creative
environment.”
Dr. Akkaraju brings over 11 years of experience in life sciences
investing and business development. Prior to joining NLV
Partners, Dr. Akkaraju was a co-founder and Managing Director of
Panorama Capital. Before forming Panorama, Dr. Akkaraju served
as Partner of J.P. Morgan Partners, LLC, where he was
responsible for leading venture investing in biotech companies.
Previously, Dr. Akkaraju held business and corporate development
positions at Genentech, where he was responsible for worldwide
partnering activities, in-licensing of therapeutics and
out-licensing of development projects. In addition, Dr. Akkaraju
was a founding member of BioStreet, an online marketplace for
biotech opportunities.
Dr. Akkaraju currently serves on the Board of Directors of
Amarin Corporation, Seattle Genetics and Pharmos Corporation, as
well as several private companies. He is the author of a number
of peer-reviewed articles, including in Science and Nature. He
received B.A. degrees in both Biochemistry and Computer Science
from Rice University and M.D. and Ph.D. degrees in Immunology
from Stanford University School of Medicine.
About NLV Partners
NLV Partners is a life science-dedicated venture capital firm
with offices in Menlo Park and New York. Founded by an
experienced team of venture capitalists with deep healthcare
industry experience, NLV Partners invests primarily in companies
focused on clinical-stage biopharmaceutical products,
early-stage medical devices and molecular diagnostics. NLV
Partners manages over $1.3 billion of assets, including NLV-I,
NLV-II and the healthcare technology portfolio of Sprout Group.
For further information, visit the NLV Partners website at
www.nlvpartners.com.
Contacts
Burns McClellan on behalf of NLV Partners
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
|
